Джим Коллинз - Как гибнут великие и почему некоторые компании никогда не сдаются

40.Источник: ©2006 CRSP Центр изучения котировок ценных бумаг Высшей школы бизнеса Чикагского университета. Авторские права защищены, www.crsp.chicagobooth.edu.

41.Из личных бесед с автором.

42.Steven Jacober, “Ames Redefines Itself at $2 Billion," Discount Merchandiser, August 1988, 22; Peter Hisey, “Herb Gilman: ‘The Concept Is So Simple,’” Discount Store News 27. no. 11 (TVIay 23, 1988): 49.

43.Ames Department Stores, Inc., “Letter to Shareholders,” 1988 Annual Report to Stockholders (Rocky Hill, CT: Ames Department Stores, Inc., 1989); Eric N. Berg, “Ames’s Rocky Retailing Marriage," New York Times, April 11, 1990.

44.Источник: ©2006 CRSP Центр изучения котировок ценных бумаг Высшей школы бизнеса Чикагского университета. Авторские права защищены, www.crsp.chicagobooth.edu.

45.Mike DufT, “Discount Veteran Ames to Liquidate After 44 Years,” DSN Retailing Today 41, no. 16 (August 26, 2002): 1.

46.Ames Department Stores, Inc., “Letter to Shareholders," 1988 Annual Report to Stockholders (Rocky Hill, CT: Ames Department Stores, Inc., 1989): Joseph Pereira, “Digesting Zayre Gives Ames Heartburn,” Wall Street Joumalf December 28, 1989; Eric N. Berg, "Ames’s Rocky Retailing Marriage," New York Times, April 11,1990; Pete Hisey, “What Went Wrong at Ames?" Discount Store News 29, no. 9 (May 7, 1990): 1.

47. Motorola, Inc., 1995 Summary Annual Report (Schaumburg, IL: Motorola, Inc., 1996).

48.John Simons, ‘‘Will R&D Make Merck Hot Again?" Fortune, July 8, 2002, 89.

49.‘‘HP Files 5,000 Patent Applications Worldwide in 2001," HP Press Release (Palo Alto: Hewlett-Packard Company), February 8, 2002.

50.Alan Farnham, “America’s Most Admired Company," Fortune, February 7,1994, 50: Marshall Loeb, "How To Grow A New Product Every Day," Fortune, November 14, 1994, 269.

51.“Where Do They Get All Those Ideas?” Machine Design, January 26,

1995, 40; Lornet Turnbull, "Ohio-Based Rubbermaid Inc. Heeds Findings from Consumer Focus Groups,” Akron Beacon Journal, February 18, 1996.

52.Wolfgang R. Schmitt, “A Growth Strategy,” Executive Excellence, August 1994,17; Tricia Welsh, “Best and Worst Corporate Reputations," Fortune, February 7, 1994, 58; Alan Famham, “America’s Most Admired Company,” Fortune, February 7, 1994, 50; Marshall Loeb, “How To Grow A New Product Every Day,” Fortune, November 14,

1994, 269; Lomet Turnbull, “Ohio-Based Rubbermaid Inc. Heeds Findings from Consumer Focus Groups," Akron Beacon Journal, February 18,1996.

53.Lee Smith, "Rubbermaid Goes Thump,” Fortune, October 2, 1995, 90; Geoffrey Colvin, “From the Most Admired to Just Acquired: How Rubbermaid Managed to Fail,” Fortune, November 23, 1998, 32.

54.Glen Gamboa, “Rubbermaid Corp. Is Proposing a Nice, Neat Solution,” Akron Beacon Journal, October 22, 1998; Glen Gamboa,

“Rubbermaid Seeks Boost Through ’Solutions’ Marketing," Akron Beacon Journal, July 28, 1997; Raju Narisetti, “Rubberrnaid’s Plan to Buy Graco Is Eclipsed by Poor Profit Forecast," Wall Street Journal, September 5, 1996; “Rubbermaid Completes Acquisition,” Discount Store News 35, no. 21 (November 4, 1996): 43; Claudia

H. Deutsch, “A Giant Awakens, To Yawns: Is Rubbermaid Reacting Too Late?” New York Times, December 22, 1996; Matt Murray, “Rubbermaid Tries to Regain Lost Stature,” Wall Street Journal, December 6, 1995; Susan Sowa, “Restructuring May Salvage Rubbermaid,” Rubber &. Plastics News 25, no. 10 (December 18, 1995): 7; Lomet Turnbull, “Ohio-Based Rubbermaid Inc. Heeds Findings from Consumer Focus Groups,” Akron Beacon Journal, February 18, 1996.

55.Geoffrey Colvin, “From the Most Admired to Just Acquired: How Rubbermaid Managed to Fail,” Fortune, November 23, 1998, 32;

Glenn Gamboa, “Rubbermaid Corp. Is Proposing a Nice, Neat Solution," Akron Beacon Journal, August 6. 1997; “Buy Merges Rubbermaid’s Products. Newell’s Management." Akron Beacon Journal. October 22. 1998; Claudia H. Deutsch, “Newell Buying Rubbermaid in $5.8 Billion Deal,” New York Times, October 22,

1998.

56.Amy Barrett and Larry Armstrong, “Merck Takes Some Growth Pills," BusinessWeek, October 12, 1998, 78; Gardiner Harris, “Cold Turkey: How Merck Intends to Ride Out a Wave of Patent Expirations,” Wall Street Journal, February 9, 2000.

57.Clark Gilbert and Ratna G. Sarkar, “Merck: Conflict and Change,” Harvard Business School, case study #9-805-079 (Boston: Harvard Business School Publishing, 2005).

58. Amy Barrett and Larry Armstrong, “Merck Takes Some Growth Pills," BusinessWeek, October 12,1998, 78.

59. Merck & Co., Inc., Merck 1998 Annual Report (Whitehouse Station, NJ: Merck & Co., Inc., 1999), 3.

60. Merck & Co., Inc., Merck 1999 Annual Report (Whitehouse Station. NJ: Merck & Co., Inc., 2000); John Simons and David Stipp. “Will Merck Survive Vioxx?" Fortune, November 1, 2004.90.

61. Eduardo Ortiz, “Market Withdrawal of Yioxx: Is It Time to Rethink the Use of COX-2 Inhibitors?" Journal of Managed Care Pharmacy'

10, no. 6 (November/December 2004): 551—554: Claire Bombardier. Loren Laine, Alise Reicin. et al. for the VIGOR Study Group. “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients With Rheumatoid Arthritis." New England Journal of Medicine 343, no. 21 (November 23. 2000): 1520—1528. http://content.nejm.org/cgi/content/full/ 343/21/1520.

62.Peter S. Kim and Alise S. Reicin. “Refecoxib, Merck and the FDA." New England Journal of Medicine 351. no. 27 (December 30, 2004): 28 75—28 78; John Simons and David Stipp, “Will Merck Survive Yioxx?" Fortune, November 1. 2004, 90.

63.Merck & Co., Inc., Annual Report 2002 (Whitehouse Station. NJ: Merck & Co., Inc., 2003); Merck & Co.. Inc., Annual Report 2004 (Whitehouse Station, NJ: Merck & Co., Inc., 2005); Susan Dentzer. “Drug Failure." Online NewsHour, November 18, 2004, http://www.pbs.oi)£/ newshour/bb/health/j u ly-dec04/vioxx n-i&html.

64.Eric J. Topol, “Failing the Public Health — Rofecoxib, Merck, and the FDA," New England Journal of Medicine 351, no. 17 (October 21.

2004): 1701 — 1709; Debabrata Mukheijee, Steven E. Nissen, and Eric J. Topol, “Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors,” Journal of the American Medical Association 286, no. 8 (August 22, 2001): 954—959; Daniel H. Solomon, Sebastian Schneeweiss, Robert J. Glynn, et al., “Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults," Circulation 109 (April 19, 2004): 2068—2073, http://circ.ahajoumals.org/cgi/content/full/109/17/2068.

65.Peter S. Kim and Alise S. Reicin, “Rofecoxib, Merck and the FDA," New England Journal of Medicine 351, no. 27 (December 30, 2004): 2875-2878.

66. Merck & Co., Inc., Annual Report 2004 (Whitehouse Station, NJ: Merck & Co., Inc., 2005), 21.

67.Brooke A. Masters and Marc Kaufman, “Painful Withdrawal for Makers of Yioxx,” Washington Post, October 18, 2004.

68. Christopher Rowland, “CEO Defends Merck on Vioxx: Confirmation of Woes Came ‘Out of Blue,'" Boston Globe, October 9, 2004, http://www.boston.com/business/articles/2GQ4/lo/Q9/ceo_defends_merck_on_vioxx; Merck & Co., Inc. “Company Statements," VIOXX® (rofecoxib)InformationCenter,http// www.merck.com/newsroom/vioxx/archive.html#company_statements.

69.John Simons and David Stipp, “Will Merck Survive Vioxx?” Fortune, November 1, 2004, 90.

70.George W. Merck, “Talk by George W. Merck at the Medical College of Virginia at Richmond," December 1, 1950.

71.Jim Collins, Good to Great: Why Some Companies Make the Leap ... And Others Don’t (New York: HarperCollins, 2001). 22. G. Christian Hill and Mike Tharp, “Stumbling Giant," Wall Street Journal, July 18, 1985.

73.Garrett G. Fagan, Emperors of Rome (Chantilly, VA: The Teaching Company Limited Partnership, 2007), audiotapes of lectures by Garrett G. Fagan, Lectures 3—6,10. тр. 73

74.Ed Viesturs and David Roberts, No Shortcuts to the Top (New York: The Doubleday Broadway Publishing Group, 2006), 158.

75.Jill Bettner, ’“Underpromise, Overperform,"’ Forbes, January 30,

1984, 88; Motorola, Inc., “Note 2 to Consolidated Financial State-

ments," 1996 Summary Annual Report (Schaumburg, IL: Motorola, Inc., 1997).

76.Sydney Finkelstein and Shade H. Sanford, “Learning from Corporate Mistakes: The Rise and Fall of Iridium," Organizational Dynamics 29, no. 2 (November 2000): 138—148.

77.Sydney Finkelstein and Shade H.Sanford, “Learning from Corporate Mistakes: The Rise and Fall of Iridium," Organizational Dynamics 29, no. 2 (November 2000): 138—148.

78.Rajiv Chandrasekaran, “Motorola’s Next Page: The Cellular Giant and Onetime Stock Star Seeks Ways to Renew Its Growth,” Washington Fost, September 29, 1996.

79.Motorola, Inc., “Letter to Stockholders,” 1997 Summary Annual Report (Schaumburg, IL: Motorola, Inc., 1998), 6.

80.Sydney Finkelstein and Shade H. Sanford, “Learning from Corporate Mistakes: The Rise and Fall of Iridium ” Organizational Dynamics 29, no. 2 (November 2000): 138—148.

81.Motorola, Inc., 1999 Proxy Statement (Schaumburg. IL: Motorola, Inc., 2000), httpy/mediaxorporate-irjiet/media.files/ irol/9o/9o829/proxies /mot.000324.1999_proxyhtm.

82.Caleb Pirtle III, Engineering the World: Stories from the First 75 Years of Texas Instruments (Dallas: Southern Methodist University Press,

2005), 153; Joan Terrall, “Texas Instruments, Incorporated: 1983,” Harvard Business School, case study #9-184-109 (Boston: Harvard Business School Publishing, 1984), 10.

83.Robert Ristelhueber, “Texas Tornado," Electronic Business 23. no. 12 (December 1997): 35.

84.Svetlana Josifovska, “Deep in the Heart of Texas Instruments." Electronic Business 26, no. 10 (October 2000): 116; Peter Burrows and Jonathan B. Levine, “TI is Moving Up in the World," BusinessWeek, August 2, 1993, 46: Jim Bartimo. “TI Bets Most of Its Marbles On Chips,” BusinessWeek, January 29, 1990. 73; Kyle Pope, “Texas Instruments Places Hopes On Chip," Wall Street Journal, March 10, 1994; Robert Ristelhueber. “Texas Tornado," Electronic Business 23, no. 12 (December 1997): 35; Caleb Pirtle III. Engineering the World: Stories from the First 75 Fears of Texas Instruments (Dallas: Southern Methodist University Press, 2005), 169-171.

85.Edward R. Tufte, Visual Explanations: Images and Quantities, Evidence and Narrative (Cheshire, CT: Graphics Press, 1997),

38—53; Diane Vaughan, The Challenger Launch Decision: Risky Technology, Culture, and Deviance at NASA (Chicago: University of Chicago Press, 1996), 278—433.